medigraphic.com
ISSN 0188-2198 (Print)

2006, Number 2

<< Back Next >>

Rev Mex Cardiol 2006; 17 (2)

Structural and functional effects of AT1 receptor blockade of angiotensin II in hypertensive population

Cardona-Muñoz EG, Ayub-Ayala M, Delgado-Hurtado JM, Armendáriz-Borunda J, Rincón-Sánchez AR, Galván-Ramírez ML, Troyo-SanRomán R, Ortuño-Sahagún D

Language: Spanish
References: 20
Page: 83-87
PDF size: 61.25 Kb.


ABSTRACT

Objective: To assess the impact of selective blockade of the AT1 receptor on the structure and the heart function in patients with mild hypertension. Study design: This Study was performed in 21 patients. The mean age was 55.4 ± 6.7. All patients underwent an overall cardiologic clinical evaluation, electrocardiographic and echocardiographic studies were performed at baseline and 6 months after treatment with 50 to 100 mg once a day oral administration of losartan. Results: Patients hadsystolic and diastolic blood pressure reduction (148 ± 12.5 vs 121 ± 9.3 y 93 ± 7.4 vs 77 ± 5.1 mmHg) with statistical significance (p ‹ 0.001). In this study there was a left ventricular mass index (LVMI) reduction from 159.46 ± 35.02 to 144.67 ± 31.51 g/m2 (p‹ 0.01), and the diastolic left ventricular function improved, supported by the shortening of the isovolumetric relaxation period from 115.32 ± 25.93 to 108.64 ± 20.95 mseg (p ‹ 0.05) and by the change of the E wave slope on transmitral flux (208.82 ± 29.55 to 222.07 ± 41.86 mseg. p ‹ 0.05). Conclusions: This study shows that the selective AT1 blockade, besides diminishing the values of arterial pressure in hypertensive patients, diminishes the left ventricular mass, and improves the diastolic function of the hypertensive patients.


REFERENCES

  1. Velásquez MO, Peralta RM, Esqueda LA, Pastelín HG, Grupo ENSA 2000, Attie F, Tapia CR. Arch Cardio Mex 2002; 72(1): 71-84.

  2. Secretaría de Salud, Epidemiología SSA. Encuesta Nacional de Enfermedades Crónicas. 1993, México: Tercera edición, Julio 1996, 25-28. ISBN 968-811-497-9.

  3. Weber KT, Janicki JS. Myocardial oxygen consumption the role of wall force and shortening. Am J Physiol 1977; 9: 776-83.

  4. Grossman W. Cardiac Hypertrophy: useful adaptation or pathologic process. Am J Med 1980; 69: 576-84.

  5. Gottdiener JS, Reda DJ, Massie BM, Matterson BJ, for the Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.

  6. Devereux RV, Palmieri V, Sharpe N. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248-1254.

  7. Dahlöf B, Zanchetti A, Díez J, Nicholls MG. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile and patients with essential hypertension and left ventricular hypertrophy. J Hipertens 2002; 20: 1855-1864.

  8. American Society of Hypertension: Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-9.

  9. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55(4): 613-618.

  10. Papademetriou V, Gottdiener JS, Fletcher RD, Freis ED. Echocardiographic assessment by computer-assisted analysis of diastolic left ventricular function and hypertrophy in borderline or mild systemic hypertension. Am J Cardiol 1985; 56: 546-50.

  11. Cohen GI et al. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996; 27: 1753-60

  12. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13(1 Part 2): 18S-24S.

  13. Colin JJ. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-07.

  14. Tudesco MA et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. Journal of Human Hypertension 1998; 12: 505-510.

  15. Lyons D, Webster J, Nigel B. Angiotensin II. Adrenergic sympathetic action in humans. Circulation 1995; 91: 1457-1460.

  16. Marsubara H. Pathophysiological role of agiotensin II type 2 receptor in cardiovascular and renal disease. Circ Res

  17. Palatini P, Visentin P, Mormino P, Mos L, Canali C, Dorigatti F et al. Structural abnormalities and not diastolic dysfunction are the earliest left ventricular changes in hypertension. Am J Hypertens 1998; 11: 147-154.

  18. Dahlöf B et al. Reversal of cardiovascular changes when treating essential hypertension. The rennin-angiotensinaldosterone system. Am J Hypertens 1992; 5: 900-911.

  19. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Circulation 1995; 91: 1450-1456.

  20. Díez J et al. Losartan-Dependent regression of myocardial fibrosis is associated reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.




2020     |     www.medigraphic.com